Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: A potential modifier of phenotype?

Sarah Hutchinson, Andre Furger, Dorothy Halliday, Daniel P. Judge, Andrew Jefferson, Harry C Dietz, Helen Firth, Penny A. Handford

Research output: Contribution to journalArticle

Abstract

FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78 ± 2.2 to 27.3 ± 2.3%) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.

Original languageEnglish (US)
Pages (from-to)2269-2276
Number of pages8
JournalHuman Molecular Genetics
Volume12
Issue number18
DOIs
StatePublished - Sep 15 2003

Fingerprint

Marfan Syndrome
Phenotype
Nonsense Codon
Alleles
Mutation
Penetrance
RNA Stability
Ribonucleases
Connective Tissue
RNA
Messenger RNA
Proteins

ASJC Scopus subject areas

  • Genetics

Cite this

Allelic variation in normal human FBN1 expression in a family with Marfan syndrome : A potential modifier of phenotype? / Hutchinson, Sarah; Furger, Andre; Halliday, Dorothy; Judge, Daniel P.; Jefferson, Andrew; Dietz, Harry C; Firth, Helen; Handford, Penny A.

In: Human Molecular Genetics, Vol. 12, No. 18, 15.09.2003, p. 2269-2276.

Research output: Contribution to journalArticle

Hutchinson, S, Furger, A, Halliday, D, Judge, DP, Jefferson, A, Dietz, HC, Firth, H & Handford, PA 2003, 'Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: A potential modifier of phenotype?', Human Molecular Genetics, vol. 12, no. 18, pp. 2269-2276. https://doi.org/10.1093/hmg/ddg241
Hutchinson, Sarah ; Furger, Andre ; Halliday, Dorothy ; Judge, Daniel P. ; Jefferson, Andrew ; Dietz, Harry C ; Firth, Helen ; Handford, Penny A. / Allelic variation in normal human FBN1 expression in a family with Marfan syndrome : A potential modifier of phenotype?. In: Human Molecular Genetics. 2003 ; Vol. 12, No. 18. pp. 2269-2276.
@article{9b01e92d222f4d4aa061c4f139291a27,
title = "Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: A potential modifier of phenotype?",
abstract = "FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78 ± 2.2 to 27.3 ± 2.3{\%}) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.",
author = "Sarah Hutchinson and Andre Furger and Dorothy Halliday and Judge, {Daniel P.} and Andrew Jefferson and Dietz, {Harry C} and Helen Firth and Handford, {Penny A.}",
year = "2003",
month = "9",
day = "15",
doi = "10.1093/hmg/ddg241",
language = "English (US)",
volume = "12",
pages = "2269--2276",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Allelic variation in normal human FBN1 expression in a family with Marfan syndrome

T2 - A potential modifier of phenotype?

AU - Hutchinson, Sarah

AU - Furger, Andre

AU - Halliday, Dorothy

AU - Judge, Daniel P.

AU - Jefferson, Andrew

AU - Dietz, Harry C

AU - Firth, Helen

AU - Handford, Penny A.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78 ± 2.2 to 27.3 ± 2.3%) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.

AB - FBN1 mutations cause Marfan syndrome (MFS), an autosomal dominant disorder of connective tissue. One of the unexplained features of MFS is the pathogenic mechanism that leads to marked inter- and intra-familial clinical variability, despite complete disease penetrance. An FBN1 deletion patient [46,XXdel(15)(q15q22.1)] was identified whose fibrillin-1 protein and mRNA levels were significantly higher than expected for a single FBN1 allele. This suggested that allelic variation in normal FBN1 expression might occur in MFS families, and have potential clinical implications particularly for those with premature termination codon (PTC) mutations who usually display low levels of expression from the mutant allele due to nonsense-mediated decay (NMD). RNA analyses identified a variable reduction in total FBN1 transcript (78 ± 2.2 to 27.3 ± 2.3%) in three related individuals carrying PTC-causing mutation 932insT, compared with unaffected control individuals. Both pulse chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated that these differences were due to variation in the expression of the normal FBN1 allele and not NMD of mutant RNA. We suggest that differences in normal FBN1 expression could contribute to the clinical variability seen in this family with MFS, and should be considered as a potential modifier of phenotype in other cases of MFS.

UR - http://www.scopus.com/inward/record.url?scp=0141702288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141702288&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddg241

DO - 10.1093/hmg/ddg241

M3 - Article

C2 - 12915484

AN - SCOPUS:0141702288

VL - 12

SP - 2269

EP - 2276

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 18

ER -